Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT00559819 |
Other study ID # |
MMoric111207 |
Secondary ID |
|
Status |
Completed |
Phase |
Phase 3
|
First received |
|
Last updated |
|
Start date |
February 2008 |
Est. completion date |
July 2022 |
Study information
Verified date |
December 2022 |
Source |
Rush University Medical Center |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
The proposed study will validate and determine sensitivity of our new driving simulator,
created to evaluate driving ability in a related study to show similar driving performance
between patients on chronic opioid treatment and a control group. Although the commercial
version of the simulator has been validated for certain populations and certain measures,
these require re-calibration for our own clinical study. The investigators propose a
prospective randomized clinical trial to evaluate driving skills under alcohol consumption
using a driving simulator. Two groups of study subjects will be utilized, with the majority
(80%) receiving alcohol and placebo at different times. A smaller set of study subjects (20%)
will be given placebo on both trials to evaluate learning effects and placebo blinding
effectiveness. Each group will take the driving test at three time points: once as a baseline
at the beginning of the study, once after the 1st dosing of the placebo and again after
dosing two of the alcohol or placebo beverage. This information will allow us to evaluate
driving ability under other potentially impairing conditions such as opioid usage.
Description:
Subjects will be recruited via discreet flyers distributed around the Rush University Medical
Campus. Subjects will be scheduled so that a maximum of 6 participants are evaluated on the
same day. Some evaluation days may fall on the weekend. Study duration is estimated at 4-5
hours, and at the completion the subjects will be driven to their respective residences.
Upon arrival subjects will complete questionnaires which contain demographic information and
measures to evaluate possible alcohol abuse issues. All subjects will be given a short
driving simulator practice and then the baseline simulator trial. Subjects will be randomized
into two groups as part of a study, with an 80% probability of selection for group A and a
20% probability of selection for Group P. Group P will only be given placebos so that any
learning effects can be estimated. In addition to the baseline, both groups will take the
full driving test two additional times each preceded by an alcohol or placebo dosing. Of
these two trials only on Trial#2 of Group A is alcohol given. Both groups will receiver
placebo on simulator Trial #1.
Alcohol trial (Group A only):
The alcohol dose will consist of a 40% alcohol (vodka) liquor in a beverage containing 2
parts orange juice and 1 part liquor. The exact amount/volume of alcohol will be determined
based on factors such as weight and sex so as to reach a peak BAC of 0.08%.
The primary contrast of interest is the comparison between the placebo and the alcohol dosed
driving simulation trials. Analyses will take place with general linear models framework,
using "Proc Mixed" to model the repeated measures design and produce accurate estimate of the
pre-planned comparisons as well as main effects and longitudinal estimates. Various outcome
variables that measure driving ability will be used, the three primary measures being: a
measure of weaving (Standard Deviation of Lateral Deviation), Reaction Time (RT) to
unexpected stimuli, and number of accidents. The placebo, Group P, will be evaluated to
estimate the effect of learning and to estimate the effectiveness of the placebo sham.